专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明公开

KR1020080005847A 신규한 삼환계 알카로이드 및 이를 함유하는 약제학적조성물 无效
标题翻译：新型三环衍生物及含有其的药物组合物
公开(公告)号：KR1020080005847A
公开(公告)日：2008-01-15
申请号：KR1020070051533
申请日：2007-05-28
申请人： 주식회사 씨트리 , 주식회사 케이티앤지
发明人： 장동조 , 윤은영 , 이건봉 , 김순옥 , 김완주
IPC分类号： C07C49/513 , C07C325/02 , C07C49/453 , C07C49/423
摘要： A tricyclic alkaloid or a pharmaceutically acceptable salt thereof is provided to improve immunosuppression, immunomodulation, anti-inflammatory and anti-cancer effects while reducing toxicity and possibility of mutagenesis. A tricyclic alkaloid or a pharmaceutically acceptable salt thereof is represented by the following formula (I) or (II). In formula (I), when R1 represents N(R5)C(X1)-A, R2 represents H, X2R6 or X2(O)n1R6; and each of R3 and R4 represents H, methyl, or a linear or branched lower alkyl; each of R5 and R6 represents H or a linear or branched lower alkyl; each of X, X1 and X2 represents O or S; and n1 is an integer of 1-2; and A represents any one of the following (a), (b), (c), (d), (e), (f) and (g).
摘要翻译：提供三环生物碱或其药学上可接受的盐以改善免疫抑制，免疫调节，抗炎和抗癌作用，同时降低毒性和诱变的可能性。三环生物碱或其药学上可接受的盐由下式（I）或（II）表示。在式（I）中，当R1表示N（R5）C（X1）-A时，R2表示H，X2R6或X2（O）n1R6; R 3和R 4各自表示H，甲基或直链或支链的低级烷基; R5和R6各自表示H或直链或支链的低级烷基; X，X1和X2各自表示O或S; n1为1-2的整数; A表示下述（a），（b），（c），（d），（e），（f）和（g）中的任何一种。

62. 发明授权

KR100622638B1 우수한 안정성을 갖는 란소프라졸 함유 약제학적 조성물및 이의 경구용 제제 失效
标题翻译：包含具有良好稳定性的兰索拉唑和包含其的口服制剂的药物组合物
公开(公告)号：KR100622638B1
公开(公告)日：2006-09-18
申请号：KR1020030021328
申请日：2003-04-04
申请人： 주식회사 씨트리
发明人： 김연환 , 김우석 , 정세영 , 김순옥 , 김완주
IPC分类号： A61K31/4439
摘要： 본 발명은 항궤양제로서 매우 유용한 란소프라졸 및 실리코알루민산나트륨으로 이루어진 약제학적 조성물 및 상기 조성물을 캅셀에 충전하여 캅셀을 장용코팅하거나, 건식 또는 습식과립을 형성하고 타정한 후 장용코팅을 하여 안정화시킨 경구용 제제에 관한 것이다. 본 발명에서는 우수한 항궤양 효과를 가지지만 산에는 극히 불안정한 란소프라졸을 실리코알루민산나트륨으로 안정화시킴으로서 산에 대한 안정성을 극대화시킨 약제학적 조성물을 제공한다.
란소프라졸, 실리코알루민산나트륨, 항궤양제

63. 发明授权

KR100460213B1 항체 함유 난황분말의 제조방법, 이로부터 제조된 난황분말 및 난황분말 함유 조성물 失效
标题翻译： 항체함유난황분말의제조방법，이로부터제조된분말및난황분말함유유조성물
公开(公告)号：KR100460213B1
公开(公告)日：2004-12-08
申请号：KR1020010014825
申请日：2001-03-22
申请人： 주식회사 씨트리
发明人： 김순옥 , 유선영 , 석철준 , 배윤의 , 이석준 , 김희주 , 김완주
IPC分类号： A61K39/395
摘要： PURPOSE: A process of preparing egg yolk powder containing antibodies treated with a grapefruit seed extract to maintain the potency of antibodies and to increase preservability and an additive to remove a fishy smell in the yolk and to increase the flavor and preservability thereof is provided. Because the composition containing the egg yolk powder is power, it is convenient to handle and take and can also be encapsulated. CONSTITUTION: The antibodies induced from strains causing various diseases in mammals are injected to laying hens. An egg yolk liquid containing an antibody is separated from the egg produced from the immunized laying hens, added with 250 to 1,000ppm grapefruit extract and 5 to 15% by weight of white sugar and heated at 60 to 70deg.C for 3 to 10min one to three times. The heat treated egg yolk liquid is spray-dried or freeze-dried. The composition comprises 40 to 50% by weight of egg yolk powder, 45 to 55% by weight of lactic acid powder, 0.5 to 1.5% by weight of silica dioxide, 0.5 to 1.5% by weight of magnesium stearate and 0.1 to 2% by weight of a sweetener.
摘要翻译：目的：提供一种制备含有用葡萄柚种子提取物处理过的抗体以维持抗体效力和增加保存性的蛋黄粉以及添加剂以除去蛋黄中的鱼腥味并增加其风味和保存性的方法。由于含有蛋黄粉的组合物具有动力，处理和取用方便，并且也可以被封装。构成：将哺乳动物中引起各种疾病的菌株诱导的抗体注射到蛋鸡中。将含有抗体的蛋黄液与由免疫蛋鸡生产的蛋分离，加入250至1,000ppm葡萄柚提取物和5至15重量％白砂糖，并在60至70℃下加热3至10分钟一次到三次。将热处理过的蛋黄液喷雾干燥或冷冻干燥。该组合物包含40至50重量％的蛋黄粉，45至55重量％的乳酸粉，0.5至1.5重量％的二氧化硅，0.5至1.5重量％的硬脂酸镁和0.1至2重量％的甜味剂的重量。

64. 发明公开

KR1020040087083A 우수한 안정성을 갖는 란소프라졸 함유 약제학적 조성물및 이의 경구용 제제 失效
标题翻译：包含在酸性条件下具有良好稳定性的兰索罗的药物组合物和含有硅酸钠的口服制剂和含有其的口服制剂
公开(公告)号：KR1020040087083A
公开(公告)日：2004-10-13
申请号：KR1020030021328
申请日：2003-04-04
申请人： 주식회사 씨트리
发明人： 김연환 , 김우석 , 정세영 , 김순옥 , 김완주
IPC分类号： A61K31/4439
CPC分类号： A61K31/4439 , A61K9/20 , A61K9/48 , Y10S514/925
摘要： PURPOSE: Provided are a pharmaceutical composition comprising lansoprazole having a good stability under acidic condition and sodium silicoaluminate, and an oral preparation containing the same. The pharmaceutical composition is useful as anti-ulcer agents. CONSTITUTION: The pharmaceutical composition is composed of lansoprazole and sodium silicoaluminate and used for the treatment of gastric and duodenal ulcers. The oral preparation is manufactured by mixing lansoprazole and sodium silicoaluminate as a stabilizing agent and coating the mixture with the enteric coating agent. The oral preparation is formulated into a tablet or a capsule.
摘要翻译：目的：提供一种包含在酸性条件下具有良好稳定性的兰索拉唑钠和硅铝酸钠的药物组合物，以及含有该组合物的口服制剂。该药物组合物可用作抗溃疡剂。构成：药物组成由兰索拉唑和硅铝酸钠组成，用于治疗胃十二指肠溃疡。口服制剂是通过将兰索拉唑和硅铝酸钠混合作为稳定剂并将该混合物与肠溶包衣剂混合来制备的。将口服制剂配制成片剂或胶囊剂。

65. 发明授权

KR100433735B1 결정형 Ⅰ을 갖는 란소프라졸의 제조방법 失效
标题翻译： 결정형I을갖는란소프라졸의제조방법
公开(公告)号：KR100433735B1
公开(公告)日：2004-06-04
申请号：KR1020010036898
申请日：2001-06-27
申请人： 주식회사 씨트리
发明人： 백용구 , 유정복 , 장동조 , 이동우 , 김민수 , 안현숙 , 박성준 , 김상훈 , 김경수 , 김완주
IPC分类号： C07D401/12
摘要： PURPOSE: Provided is a modification and purification method of Lansoprazole (crystal form II) into Lansoprazole (crystal form I) which is thermodynamically stable and is used as a drug. Lansoprazole, represented by the formula(I), is an inhibitor of proton pump(anti-ulcer agent), has strong antibacterial activity and excellent pharmacological activity, and is thus useful as a therapeutic agent for stomach ulcer. CONSTITUTION: The method comprises the steps of: mixing 1wt.% of Lansoprazole (crystal form II) and 1-100wt.% of an organic solvent; filtering the mixture; and drying the filtrate. The solvent is selected from the groups of ester containing methyl acetate and ethyl acetate; halogenated hydrocarbon such as methylene chloride and chloroform; ethers including tetrahydrofuran, ethyl ether, isopropyl ether and petroleum ether; hydrocarbons with more than 5 carbons such as pentane, hexane, heptane cyclohexane; nitriles such as acetonitrile; ketones such as acetone; and a mixture thereof.
摘要翻译：用途：提供一种将兰索拉唑（晶形II）改性和纯化为兰索拉唑（晶型I）的方法，该兰索拉唑是热力学稳定的并用作药物。由式（I）表示的兰索拉唑是质子泵（抗溃疡剂）的抑制剂，具有强抗菌活性和优异的药理学活性，因此可用作胃溃疡的治疗剂。构成：该方法包括以下步骤：将1重量％的兰索拉唑（晶形II）和1-100重量％的有机溶剂混合; 过滤混合物; 并干燥滤液。溶剂选自含有乙酸甲酯和乙酸乙酯的酯; 卤代烃如二氯甲烷和氯仿; 醚类包括四氢呋喃，乙醚，异丙醚和石油醚; 具有多于5个碳的烃，如戊烷，己烷，庚烷环己烷; 腈如乙腈; 酮如丙酮; 及其混合物。

66. 发明公开

KR1020030000779A 결정형 Ⅰ을 갖는 란소프라졸의 제조방법 失效
标题翻译：兰索唑晶体形态的修饰和纯化方法
公开(公告)号：KR1020030000779A
公开(公告)日：2003-01-06
申请号：KR1020010036898
申请日：2001-06-27
申请人： 주식회사 씨트리
发明人： 백용구 , 유정복 , 장동조 , 이동우 , 김민수 , 안현숙 , 박성준 , 김상훈 , 김경수 , 김완주
IPC分类号： C07D401/12
摘要： PURPOSE: Provided is a modification and purification method of Lansoprazole (crystal form II) into Lansoprazole (crystal form I) which is thermodynamically stable and is used as a drug. Lansoprazole, represented by the formula(I), is an inhibitor of proton pump(anti-ulcer agent), has strong antibacterial activity and excellent pharmacological activity, and is thus useful as a therapeutic agent for stomach ulcer. CONSTITUTION: The method comprises the steps of: mixing 1wt.% of Lansoprazole (crystal form II) and 1-100wt.% of an organic solvent; filtering the mixture; and drying the filtrate. The solvent is selected from the groups of ester containing methyl acetate and ethyl acetate; halogenated hydrocarbon such as methylene chloride and chloroform; ethers including tetrahydrofuran, ethyl ether, isopropyl ether and petroleum ether; hydrocarbons with more than 5 carbons such as pentane, hexane, heptane cyclohexane; nitriles such as acetonitrile; ketones such as acetone; and a mixture thereof.
摘要翻译：目的：提供兰索拉唑（晶型II）作为热力学稳定并用作药物的兰索拉唑（晶型I）的改性和纯化方法。由式（I）表示的兰索拉唑是质子泵（抗溃疡剂）的抑制剂，具有强的抗菌活性和优异的药理活性，因此可用作胃溃疡的治疗剂。构成：该方法包括：将1重量％的兰索拉唑（晶型II）和1-100重量％的有机溶剂混合; 过滤混合物; 并干燥滤液。溶剂选自含有乙酸甲酯和乙酸乙酯的酯基; 卤代烃如二氯甲烷和氯仿; 醚类，包括四氢呋喃，乙醚，异丙醚和石油醚; 具有5个以上碳原子的烃，如戊烷，己烷，庚烷环己烷; 腈类如乙腈; 酮类如丙酮; 及其混合物。

67. 发明授权

KR100338921B1 1,3-벤조디티올-2-일리움 테트라플루오로보레이트의제조방법 失效
标题翻译：制备1,3-苯并二硫醇-2-基四氟硼酸盐
公开(公告)号：KR100338921B1
公开(公告)日：2002-05-30
申请号：KR1020000001859
申请日：2000-01-15
申请人： 주식회사 씨트리
发明人： 이태석 , 유창현 , 김경수 , 유정복 , 박성준 , 김완주
IPC分类号： C07D339/06
摘要： 본 발명은 1,3-벤조디티올-2-일리움 테트라플루오로보레이트를 제조하는 방법을 제공하기 위한 것으로, 1,4-다이옥산에 용해시킨 안트라닐산으로부터 2-(3-메틸부톡시)-1,3-벤조디티올을 합성한 후 분리 단계 없이 연속해서 비양성자성 비극성 유기용매를 첨가함과 동시에 사불화붕소수소산-디에틸에테르 용액 또는 삼불화붕소 에테르콤플렉스를 첨가하여서 1,3-벤조디티올-2-일리움 테트라플루오로보레이트(BDTF)를 제조하는 방법인 것이다.
본 발명의 방법은 종래 방법의 문제점인 진한 색깔과 낮은 수율, 불안정성 등을 해결하여 높은 안정성과 옅은 색깔을 띠는 결정성 BDTF를 좀 더 간단하고, 간편하게, 높은 수율로 제조할 수 있는 방법인 것이다.

68. 发明公开

KR1020010073294A 항혈액응고성 살서제인 4-하이드록시쿠마린 중간체의제조방법 失效
标题翻译：制备抗血红蛋白4-羟基喹诺酮中间体的方法
公开(公告)号：KR1020010073294A
公开(公告)日：2001-08-01
申请号：KR1020000001555
申请日：2000-01-13
申请人： 주식회사 씨트리
发明人： 김중영 , 김경수 , 김완주
IPC分类号： C07C51/00
摘要： PURPOSE: A method for manufacturing an anti-blood coagulating rodenticide 4-hydroxycoumarin intermediate is provided to manufacture an anti-blood coagulating rodenticide 4-hydroxy-3- £1,2,3,4-tetrahydro-3-{4-(4-trifluoromethylbenzyloxy)phenyl}-1-naphthyl|coumarin intermediate which is represented in 3-(4-methoxy)phenyl-4-phenylbutanoic acid simply and in a high yield. CONSTITUTION: The method for manufacturing 4-hydroxycoumarin intermediate represented as in the following structural formula (II) comprises a first step of manufacturing a compound represented in the following structural formula (III) by reacting benzyl halide with alkylacrylate under palladium catalyst; a second step of manufacturing a compound represented in the following structural formula (IV) by carrying out the reaction under the palladium catalyst similarly as in the first step; a third step of manufacturing a compound represented as in the following structural formula (V) by reducing a compound of the structural formula (IV) obtained in the second step through hydrogenation reaction using palladium catalyst; and a fourth step of performing the next steps of saponification reaction and acid treatment without separation of a compound of the structural formula (V).
摘要翻译：目的：提供一种制备抗凝血杀鼠剂4-羟基香豆素中间体的方法，以制备抗凝血灭鼠剂4-羟基-3-（1,2,3,4-四氢-3- {4-（4 三氟甲基苄氧基）苯基} -1-萘基|香豆素中间体，其简单且高产率代表在3-（4-甲氧基）苯基-4-苯基丁酸中。构成：如以下结构式（II）所示的制备4-羟基香豆素中间体的方法包括通过在钯催化剂下使苄基卤与烷基丙烯酸酯反应来制备下述结构式（III）所示化合物的第一步骤; 通过与第一步骤类似地在钯催化剂下进行反应来制造下述结构式（IV）所示的化合物的第二步骤; 通过使用钯催化剂通过氢化反应将通过第二步获得的结构式（IV）的化合物还原，制备如下结构式（V）表示的化合物的第三步骤; 以及在不分离结构式（V）的化合物的情况下进行皂化反应和酸处理的下一步骤的第四步骤。

69. 发明公开

KR1020000055522A 이미페넴의 제조방법 失效
标题翻译： IMIPENEM的合成方法
公开(公告)号：KR1020000055522A
公开(公告)日：2000-09-05
申请号：KR1019990004179
申请日：1999-02-08
申请人： 주식회사 씨트리
发明人： 김경수 , 이태석 , 육진수 , 윤정인 , 윤병훈 , 김완주
IPC分类号： C07D477/20
CPC分类号： Y02P20/55
摘要： PURPOSE: Provided is a synthetic method of imipenem which can easily remove a protecting group by using allyl group as the protecting group of 2-carboxy group. CONSTITUTION: A synthetic method comprises the steps of: condensing bicyclic ketoester of formula(II) and a phosphochloridate derivative in the presence of base to prepare a phosphate derivative of formula(III); coupling 2-aminoethantiol hydrochlorate with the produced phosphate derivative of formula(III) in the container to prepare a thienamycin derivative of formula(IV); reacting the produced thienamycin derivative of formula(IV) with benzylimidate in the container to prepare an imipenem derifative of formula(V) with carboxy group as a protecting group; and demasking the imipenem derivative produced using a moupholine dervative and tetrakis triphenylphosphin paladium.
摘要翻译：目的：提供亚胺培南的合成方法，通过使用烯丙基作为2-羧基的保护基，可以容易地除去保护基。构成：合成方法包括以下步骤：在碱存在下将式（II）的双环酮酯和磷酸氯代衍生物缩合制备式（III）的磷酸酯衍生物; 将所述产生的式（III）的磷酸酯衍生物与所述式（III）的磷酸酯衍生物偶联在容器中以制备式（IV）的噻吩霉素衍生物; 使制备的式（Ⅳ）噻吩甲酰胺衍生物与苄基亚氨酸酯在容器中反应以制备具有羧基作为保护基团的式（Ⅴ）亚胺培南衍生物; 并使用莫匹罗线虫和四苯基膦化合物制备亚胺培南衍生物。

70. 发明授权

KR102044676B1 생체적합성 고분자 기반 아픽사반 함유 미립구의 제조방법 有权
公开(公告)号：KR102044676B1
公开(公告)日：2019-11-14
申请号：KR1020190035355
申请日：2019-03-27
申请人： 주식회사 씨트리
发明人： 정두용 , 이상휘 , 김미정 , 김미정 , 김완주 , 주소경
IPC分类号： A61K9/16 , A61K31/437

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式